|
| 重复经颅磁刺激治疗对血管性帕金森综合征运动症状的影响* |
| Effects of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms of Vascular Parkinsonism |
| 投稿时间：2026-03-27 修订日期：2026-05-14 |
| DOI： |
| 中文关键词: 血管性帕金森综合征 重复经颅磁刺激 运动功能 脑内神经递质 康复治疗 |
| 英文关键词: Vascular Parkinsonism repetitive transcranial magnetic stimulation motor function intracerebral neurotransmitters rehabilitation therapy |
| 基金项目:]2023年济宁市重点研发计划项目编号：2023YXNS209 |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 血管性帕金森综合征由脑血管病变所致，可造成患者运动能力下降、生活质量降低。重复经颅磁刺激（rTMS）作为无创神经调控手段，在多种神经系统疾病中展现出应用潜力，但其对血管性帕金森综合征的治疗效果仍需进一步验证。目的：探讨rTMS联合常规药物对血管性帕金森综合征患者运动功能的改善作用及临床安全性。方法：选取2023年1月—2025年10月在山东省戴庄医院神经内科收治的60例确诊患者，随机分为常规治疗组与联合治疗组。常规治疗组仅给予左旋多巴治疗，联合治疗组在左旋多巴基础上加用rTMS干预。干预2周后，比较治疗前后采用MDS-UPDRS-Ⅲ量表、PDADL量表评估患者运动功能及日常生活能力。结果：联合治疗组干预2周后运动功能及日常活动能力评分较治疗前均有不同程度的下降，但两组间最终评分值的比较差异无统计学意义（P > 0.05）。进一步分析评分改善的净差值可见，联合治疗组的MDS-UPDRS-Ⅲ量表、PDADL量表下降幅度（1.93±1.48）分、（2.7±0.46）分，均明显大于常规治疗组（0.67±1.18）分、（2.33±0.66）分，差异具有统计学意义（t=3.65 t=2.48，P<0.05）。两组不良事件发生率相近（P > 0.05），且未出现严重不良反应。结论：在常规药物治疗基础上联合rTMS，短期可显著改善血管性帕金森综合征患者近期的运动症状，整体安全性良好，具备一定的临床推广价值。 |
| 英文摘要: |
| Sixty patients with a confirmed diagnosis of vascular parkinsonism (VP) were randomly divided into two groups: a combination treatment group and a control group. The control group received levodopa as a single therapeutic agent, while the combination group was treated with levodopa combined with repetitive transcranial magnetic stimulation (rTMS). Motor function and daily living ability were evaluated by MDS-UPDRS-III and PDADL scales before and after treatment.Results After 2 weeks of intervention, both motor function and activities of daily living (ADL) scores in the combined treatment group showed a certain degree of decline relative to baseline. Nevertheless, the post-intervention scores between the two groups showed no statistically significant difference (P > 0.05). Further analysis of the net score improvements showed that the combined?treatment group exhibited larger reductions in the MDS?UPDRS?Ⅲ scale (1.93 ± 1.48 points) and PDADL scale (2.7 ± 0.46 points). These decreases were significantly greater than those observed in the conventional?treatment group (0.67 ± 1.18 points and 2.33 ± 0.66 points, respectively), with statistically significant intergroup differences (t = 3.65, t = 2.48, P < 0.05). No serious adverse events were reported in either group throughout the study period.Conclusion In addition to conventional drug treatment, combined with rTMS, it can significantly improve the motor symptoms of patients with vascular Parkinsonism in the short term. The overall safety is good and it has certain clinical promotion value. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
